Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.
- Author:
Kyung Jin MIN
1
;
Sang Hoon KWON
;
Sunghoon KIM
;
Hyun Jung KIM
;
Seok Ju SEONG
;
Yong Jung SONG
;
Jin Woo SHIN
;
Keun Ho LEE
;
Myong Cheol LIM
;
Hyun Hoon CHUNG
;
Woong JU
;
Jin Hwa HONG
;
Jeong Won LEE
;
Jae Weon KIM
;
Duk Soo BAE
;
Jae Kwan LEE
Author Information
- Publication Type:Review
- Keywords: Human Papillomavirus Vaccine; Uterine Cervical Neoplasms
- MeSH: Adolescent; Adult; Age Factors; Child; Female; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage/adverse effects/therapeutic u; Humans; Middle Aged; Papillomavirus Vaccines/administration & dosage/adverse effects/*therapeutic use; *Practice Guidelines as Topic; Republic of Korea; Treatment Outcome; Uterine Cervical Neoplasms/*prevention & control; Young Adult
- From:Journal of Gynecologic Oncology 2016;27(3):e30-
- CountryRepublic of Korea
- Language:English
- Abstract: After human papillomavirus (HPV) vaccine guidelines published by Korean Society of Gynecologic Oncology (KSGO) in 2011, new studies have been published, leading to additional data regarding efficacy, safety, number of vaccination rounds, and ideal age of vaccine administration. We searched and reviewed the literatures focused on the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the ability of cross-protection of each HPV preventive vaccine. The KSGO has revised the previous guideline based on the results of the above studies.
